Taconic Biosciences Launches New COVID-19 Mouse Model
Expands COVID-19 Research Toolkit with novel hACE2 AC22 Mouse
RENSSELAER, N.Y., April 29, 2021 (GLOBE NEWSWIRE) Taconic Biosciences, a global leader in providing drug discovery animal model solutions, announces the launch of a new COVID-19 mouse model. This human ACE2 (hACE2) transgenic mouse expands Taconic s COVID-19 research toolkit.
In October 2020, Taconic launched its first hACE2 model. The AC70 mouse experiences a lethal response to infection by SARS-CoV-2, the virus that causes COVID-19. Conversely, the new AC22 mouseis lethality-resistant, enabling therapeutic, vaccine, and post-infection symptom research.
Although various hACE2 mouse models of lethal SARS-CoV-2 infection exist, the hACE2 AC22 lethality-resistant model is important because it permits study of sublethal infection. Most humans infected with SARS-CoV-2 survive, and an animal model which replicates sublethal disease and recovery is needed. The hACE2 AC2
Taconic Biosciences Launches New COVID-19 Mouse Model
Expands COVID-19 Research Toolkit with novel hACE2 AC22 Mouse
RENSSELAER, N.Y., April 29, 2021 (GLOBE NEWSWIRE) Taconic Biosciences, a global leader in providing drug discovery animal model solutions, announces the launch of a new COVID-19 mouse model. This human ACE2 (hACE2) transgenic mouse expands Taconic’s COVID-19 research toolkit.
In October 2020, Taconic launched its first hACE2 model. The AC70 mouse experiences a lethal response to infection by SARS-CoV-2, the virus that causes COVID-19. Conversely, the new AC22 mouse is lethality-resistant, enabling therapeutic, vaccine, and post-infection symptom research.
Although various hACE2 mouse models of lethal SARS-CoV-2 infection exist, the hACE2 AC22 lethality-resistant model is important because it permits study of sublethal infection. Most humans infected with SARS-CoV-2 survive, and an animal model which replicates sublethal disease and recovery is needed. The hAC
Taconic Biosciences Expands Immuno-oncology Animal Model Portfolio
Critical Jh Syngeneic Tumor Model Host Now Available on a B6 Background
RENSSELAER, N.Y., Jan. 18, 2021 (GLOBE NEWSWIRE) Taconic Biosciences, a global leader in providing drug discovery animal model solutions, announces an expansion of its immuno-oncology portfolio.
Immuno-oncology is a leading research priority because it uses the body s own immune system to effectively treat some types of cancer. Syngeneic tumor animal models play a critical role because they use standard inbred mice that have a competent immune system, which is required to evaluate immune-modulating therapies. These models are engrafted with mouse tumors derived from the same strain background; this genetic similarity between tumor and host prevents the host from rejecting the tumor.
Lanesboro tax levy lower than last year s fillmorecountyjournal.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from fillmorecountyjournal.com Daily Mail and Mail on Sunday newspapers.